Skip to content

Esther O'Shea

11 papers in the library · 8 citations · publishing 2003-2021

Papers

Sort Most recent Most cited

Increased kynurenine concentration attenuates serotonergic neurotoxicity induced by 3,4-methylenedioxymethamphetamine (MDMA) in rats through activation of aryl hydrocarbon receptor.

Neuropharmacology February 16, 2021 C. Abuin-Martínez, Rebeca Vidal, Maria D Gutierrez-Lopez et al.

3,4-Methylenedioxymethamphetamine (MDMA) is an amphetamine derivative that has been shown to produce serotonergic damage in the brains of primates, including humans, and of rats. Tryptophan, the precursor of serotonin, is primarily degraded through the kynurenine (KYN) pathway, producing among others KYN, the main metabolite of this route. KYN has been reported as an endogenous agonist of the...

3,4-Methylenedioxymethamphetamine (MDMA, ecstasy) produces edema due to BBB disruption induced by MMP-9 activation in rat hippocampus.

Neuropharmacology March 16, 2017 Mercedes Pérez-Hernández, María Encarnación Fernández-Valle, Ana Rubio-Araiz et al.

The recreational drug of abuse, 3,4-methylenedioxymethamphetamine (MDMA, ecstasy) disrupts blood-brain barrier (BBB) integrity in rats through an early P2X7 receptor-mediated event which induces MMP-9 activity. Increased BBB permeability often causes plasma proteins and water to access cerebral tissue leading to vasogenic edema formation. The current study was performed to examine the effect of...

Current preclinical studies on neuroinflammation and changes in blood-brain barrier integrity by MDMA and methamphetamine.

Neuropharmacology December 2014 Esther O'Shea, Andrés Urrutia, Alfred Richard Green et al.

The blood-brain barrier (BBB) is essential in the maintenance of brain homeostasis both by preserving normal brain functioning and also by protecting the brain from exposure to a range of potentially harmful substances. This review presents some of the evidence of BBB disruption following exposure to the substituted amphetamines 3,4-methylenedioxymethamphetamine (MDMA, 'ecstasy') and...

DOI: 10.1016/j.neuropharm.2014.02.015 (opens in new tab) Full text (opens in new tab) 3,4-methylenedioxymethamphetamine Basal lamina proteins Blood–brain barrier disruption Igg extravasation +1

Increased interleukin-1β levels following low dose MDMA induces tolerance against the 5-HT neurotoxicity produced by challenge MDMA

Journal of Neuroinflammation December 1, 2011 Andrea Mayado, Elisa Torres, Maria D Gutierrez-Lopez et al. 8 citations

AbstractBackgroundPreconditioning is a phenomenon by which tolerance develops to injury by previous exposure to a stressor of mild severity. Previous studies have shown that single or repeated low dose MDMA can attenuate 5-HT transporter loss produced by a subsequent neurotoxic dose of the drug. We have explored the mechanism of delayed preconditioning by low dose MDMA.MethodsMale Dark Agouti...

A study on the mechanisms by which minocycline protects against MDMA ('ecstasy')-induced neurotoxicity of 5-HT cortical neurons.

Neurotoxicity Research August 2010 Laura Orío, Noemi Llopis, Elisa Torres et al.

3,4-Methylenedioxymethamphetamine (MDMA, 'ecstasy') is a selective 5-HT neurotoxin in rat brain which has been shown to produce acute neuroinflammation characterized by activation of microglia and release of interleukin-1beta (IL-1beta). We aimed to determine whether or not minocycline, a semi-synthetic tetracycline antibiotic capable of inhibiting microglial activation, could prevent the...

Dopamine transporter down-regulation following repeated cocaine: implications for 3,4-methylenedioxymethamphetamine-induced acute effects and long-term neurotoxicity in mice.

British Journal of Pharmacology December 10, 2009 Inés Peraile, Elisa Torres, Andrea Mayado et al.

Background and purpose: 3,4-Methylenedioxymethamphetamine (MDMA) and cocaine are two widely abused psychostimulant drugs targeting the dopamine transporter (DAT). DAT availability regulates dopamine neurotransmission and uptake of MDMA-derived neurotoxic metabolites. We aimed to determine the effect of cocaine pre-exposure on the acute and long-term effects of MDMA in mice. Experimental...

Administration of MDMA to ethanol-deprived rats increases ethanol operant self-administration and dopamine release during reinstatement.

The International Journal of Neuropsychopharmacology August 2009 Guillermo Moreno-Sanz, Esther O'Shea, Laura Orío et al.

Recreational use of (±)-3,4-methylenedioxymethamphetamine (MDMA, ecstasy) is often associated with other drugs, among which ethanol (EtOH) is one of the most common. However, little is known about how neurochemical sensitization produced by MDMA can modulate EtOH abuse. In this study we used EtOH operant self-administration tasks to investigate the effect of several low doses (0.33, 1.0 and 3.0...

MDMA and Other “Club Drugs”

Handbook of Contemporary Neuropharmacology March 2, 2007 María Isabel Colado, Esther O'Shea, Alfred Richard Green

AbstractThe use of the club drugs 3, 4‐methylenedioxymethamphetamine (MDMA, “ecstasy”), gamma‐hydroxybutyrate (GHB), flunitrazepam (Rohypnol), ketamine and LSD is a popular practice among young people especially during all‐night dance parties or “raves“ due to their ability to enhance social experiences and/or alter perception. These substances belong to different classes of drugs: MDMA is an...

A review of the mechanisms involved in the acute MDMA (ecstasy)-induced hyperthermic response.

European Journal of Pharmacology October 1, 2004 Alfred Richard Green, Esther O'Shea, María Isabel Colado

The predominant severe acute adverse effect following ingestion of 3,4-methylenedioxymethamphetamine (MDMA, ecstasy) by recreational users is hyperthermia which can induce other associated clinical problems and occasionally death. There is no pharmacologically specific treatment. MDMA also induces dose-dependent hyperthermia in experimental animals. This review examines the consequences of MDMA...

Synthesis, in vitro formation, and behavioural effects of glutathione regioisomers of alpha-methyldopamine with relevance to MDA and MDMA (ecstasy).

Brain Research October 17, 2003 Neil Easton, Jeff Fry, Esther O'Shea et al.

Administration of 3,4-methylenedioxymethamphetamine (MDMA) or 3,4-methylenedioxyamphetamine (MDA) to rats produces serotonergic nerve terminal degeneration. However, they are not neurotoxic when injected directly into the brain, suggesting the requirement for peripheral metabolism of MDMA to a neurotoxic metabolite. Alpha-methyldopamine (alpha-MeDA) is a major metabolite of MDA. There are...

The pharmacology and clinical pharmacology of 3,4-methylenedioxymethamphetamine (MDMA, "ecstasy").

Pharmacological Reviews September 2003 Alfred Richard Green, Annis O. Mechan, J Martin Elliott et al.

The amphetamine derivative (+/-)-3,4-methylenedioxymethamphetamine (MDMA, ecstasy) is a popular recreational drug among young people, particularly those involved in the dance culture. MDMA produces an acute, rapid enhancement in the release of both serotonin (5-HT) and dopamine from nerve endings in the brains of experimental animals. It produces increased locomotor activity and the serotonin...